The result was consistent with the correlation analysis of MAP4K1 immunoreactivity scores (derived from the staining in Fig 1) with the Ki67-positive rate in human glioma samples (Fig 4F), further confirming an oncogenic role of MAP4K1 in gliomas. This evidence concerns the gene MAP4K1 and central nervous system cancer.